Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; trometamol; water for injections; calcobutrol - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: trometamol; water for injections; hydrochloric acid; calcobutrol sodium - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: trometamol; calcobutrol sodium; water for injections; hydrochloric acid - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: trometamol; calcobutrol sodium; water for injections; hydrochloric acid - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: trometamol; water for injections; hydrochloric acid; calcobutrol sodium - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; maize starch - inoperable prostatic carcinoma. because of its anti-androgenic effect cyprostat is indicated for the treatment of inoperable prostatic carcinoma in patients who have failed primary hormonal manipulation or who are at risk from cardiovascular disease and/or intolerant of oestrogen therapy. indications as at 18 may 2005 : inoperable prostatic carcinoma. * to suppress flare with initial lhrh analogues therapy. * in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred. * in the treatment of hot flushes in pateinets treated with lhrh analogues or who have had orchiectomy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; povidone - inoperable prostatic carcinoma. because of its anti-androgenic effect androcur is indicated for the treatment of inoperable prostatic carcinoma in patients who have failed primary hormonal manipulation or who are at risk from cardiovascular disease and/or who are intolerant of oestrogen therapy. indications as at 1 june 1995: inoperable prostatic carcinoma to suppress 'flare' with initial lhrh analogue therapy; in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 623.4 mg/ml - injection - excipient ingredients: trometamol; sodium calcium edetate; water for injections; dilute hydrochloric acid; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 623.4 mg/ml - injection - excipient ingredients: trometamol; dilute hydrochloric acid; water for injections; sodium calcium edetate; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 623.4 mg/ml - injection - excipient ingredients: trometamol; water for injections; dilute hydrochloric acid; sodium calcium edetate; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.